awmsg logo



diamorphine hydrochloride (Ayendi®)


Reference No. 2406


Appraisal information

diamorphine hydrochloride (Ayendi®) 720 micrograms nasal spray
diamorphine hydrochloride (Ayendi®) 1600 micrograms nasal spray


Company: Wockhardt UK Ltd
BNF category: Central nervous system
NMG meeting date: 09/10/2019
AWMSG meeting date: 13/11/2019
   
   
Submission Type: Limited Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of acute severe nociceptive pain in children and adolescents 2 to 15 years of age in a hospital setting. Diamorphine hydrochloride nasal spray should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring
AWMSG Secretariat Appraisal Report (ASAR)
Download
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download